The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
More info
The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.
More info
Launched in 2017, OFF-X has now reached 500,000 curated safety alerts corresponding to almost 15,000 targets of pharmacological interest and almost 14,500 drugs and biologics.
More info

Our advanced data analytics solutions address the challenges of molecular and biological complexity in drug discovery.

We connect emerging data sources and life science content into advanced knowledge management platforms that deliver meaningful biomedical intelligence.

Learn more about our solutions